Join us as we bring you the latest highlights from the American Diabetes Association (ADA) 2026 Scientific Sessions in New Orleans, LA, USA, taking place 5-8 June 2026!

The sessions that we will be focusing on:

• The Benefits of Glucagon/GLP-1 Receptor Dual Agonism: Insights from the SYNCHRONIZE™ Phase 3 Studies of Survodutide
• Unlocking the Next Frontier in Treatment of Obesity and Type 2 Diabetes with Retatrutide: A Triple Agonist, Activating the GIP, GLP-1 and Glucagon Receptors (TRANSCEND-T2D-1 and TRIUMPH-1 Results)
• REIMAGINE 1, 2, 3: Leveraging Amylin and GLP-1 for Type 2 Diabetes Care with CagriSema
• A Phase 2b, Randomized, Double-Blind, Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy, Safety, and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus

We will providing a highlight videos at the end of the conference. Click here to watch the highlight videos as they become available.

For any enquiries, please contact the ADS Secretariat via email to ads@diabetessociety.com.au